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Summary. Recombinant adenoviruses, poxviruses, and plasmid DNA vaccines encoding different hepatitis B virus
(HBV)/murine cytomegalovirus (MCMV) protein chimeras were used to immunize mice. Processing of the chimeras resulted
in presentation of a protective Ld/CD8+ T-cell epitope of the immediate early 1 protein pp89 (IE1 pp89) of MCMV to the
immune system. Different levels of immunogenicity were observed depending on: (i) the type of viral vector used, (ii) whether
the antigens were included in the cellular secretion pathway, and (iii) the location of the protective epitope within the chimeric
protein. An adenovirus expressing a secretory HBV core protein with the MCMV epitope in its C-terminus induced the high-
est immune response. When the most immunogenic adenovirus and vaccinia virus were used in a heterologous prime-boost
immunization protocol, even higher levels of epitope-specific T cells were obtained. Furthermore, responses were protective
against a challenge with MCMV, inducing up to a 96% reduction of viral load in immunized animals, as determined by a sen-
sitive real-time PCR assay. Together, these results confirmed previous observations of the efficient use of adenoviral and poxvi-
ral vectors in prime-boost protocols for immunization against diseases whose resolution depends on cellular immunity, as well
as the aptness of correctly designed chimeric carrier proteins to facilitate this goal. [Int Microbiol 2007; 10(4):261-269]
Key words: cytomegalovirus · recombinant adenovirus · vaccines · prime-boost immunization · cellular immunity
Introduction
The induction of sufficient antigen-specific adaptive T-cell
responses remains a challenge in vaccinology. In the search
for tools that could help in this process, recombinant viruses
have emerged during the last 20 years as promising vectors
to efficiently induce cell-mediated immunity (CMI) against
transgenic products [15,16,20,21,28–30,34]. Recombinant
viruses can be used to express foreign proteins inside host
cells, mimicking intracellular infections caused by pathogen-
ic microorganisms but avoiding the associated deleterious
effects. Such specialization allows immune cells to process
and present those antigens through the classical major histo-
compatibility complex class I (MHC-I) loading pathway.
Consequently, this approach results in the very efficient
induction of CD8+ T cells. 
If insufficient levels of immunity are elicited after
immunization with an experimental vaccine, a prime-boost
immunization strategy can be employed, in which the sequen-
tial inoculation of a second vaccine is added to the immuniza-
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tion protocol. This strategy was first described in 1993, in a
study in which two viral vectors (influenza and vaccinia virus-
es) were tested in a model of murine malaria [17]. The authors
observed that the two vectors induced unexpectedly high levels
of CD8+ T cells in experimental animals. Since then, a myriad
of different prime-boost protocols using a wide variety of re-
combinant and non-recombinant immunogens have been devel-
oped as vaccines against many infectious diseases [10,31]. Our
initial contribution to this line of research was based on the same
original parasite model and consisted of a new prime-boost pro-
tocol that combined a recombinant adenovirus and a poxvirus.
This approach resulted in complete protection against malaria in
100% of the immunized animals [3,32]. 
Here we present the results of a new study of prime-boost
protocols using a classic herpesvirus model, murine
cytomegalovirus (MCMV) infection. Protective antiviral
immune responses mediated by CD8+ T lymphocytes against
the viral nuclear phosphoprotein pp89 are extensively des-
cribed. An epitope of pp89 (168-YPHFMPTNL-176) that is rec-
ognized by cytotoxic T lymphocytes (CTLs) of mice bearing
the Ld MHC-I molecule encompasses the optimal antigenic
sequence [7,9]. This peptide was described several years ago
as the main CD8 target during acute MCMV infection.
Recent reports further demonstrated that CD8+ T cells against
this epitope are also persistent in vivo [27]. It was also shown
that T cells of this specificity evolve to an effector-memory
phenotype [13] and are involved in the “silencing/desilencing
and immune sensing hypothesis”, thus participating in the
immunosurveillance of MCMV latency [33].
The nonanpeptide YPHFMPTNL was previously tested as
an experimental vaccine for MCMV infection using several
forms of presentation, including attenuated MCMV vaccines
[25], synthetic peptides, recombinant vaccinia viruses [8,9,
11], and plasmid DNA vaccines [12]. All of them induced
some level of protection against infection by MCMV. How-
ever, adequate vaccination vectors are not the only important
factor in achieving good induction of T cells; optimization of
the processing and presentation of the relevant antigen(s) to
the host immune system is also essential. Over the last 15
years, we have carried out several studies in which the core
protein (HBc) or the e protein (HBe) of HBV [8,11,26] were
used to generate different HBV/MCMV chimeras, with the
MCMV epitope positioned at different locations within the
HBV protein. In addition, the effects of epitope-flanking
residues and signal peptides that confer secretory properties
to the antigens were investigated.
Proceeding from the insight gained from these studies, we
developed a working hypothesis stating that: (i) a prime-
boost protocol using adenoviruses and vaccinia viruses
would be extremely efficient at inducing T-cell responses;
and (ii) recombinant viruses encoding optimized 168-YPHFM
PTNL-176/HBe and HBc chimeric proteins should be capable
of inducing unprecedented levels of immunity against
MCMV and thus better protect experimental animals against
infection. 
Materials and methods
Animals and immunizations. BALB/c mice were bred at the
CEBIO/UFMG and Biotex/IRR (Fiocruz) animal facilities, in Belo Horizonte,
Brazil, and used according to the ethical guidelines of both institutions. DNA
vaccines (pMV100 derivatives) were administered as 100-μg doses of a
Qiagen (CA, USA) endotoxin-free plasmid preparation administered intra-
muscularly three times, at 3-week intervals, to the mouse inner thigh muscle
in a final volume of 50 μl per injection. Adenoviruses were administered intra-
dermally at a dose of 5 × 108 plaque-forming units (PFU) per animal to both
sides of the tail in a final volume of 100 μl. Vaccinia (5 × 107 PFU) recombi-
nants were administered intraperitoneally in a final volume of 200 μl. 
Vectors. Plasmid DNA vaccines were generated using standard molecular
biology techniques. Foreign sequences were cloned in pMV100, a plasmid con-
taining a mammalian expression cassette formed by a cytomegalovirus imme-
diate-early 1 (CMV-IE1) promoter and polyadenylation signal (CMV-polyA;
kindly donated by Dr. G.W.G Wilkinson, University of Wales College of
Medicine, Cardiff). From this vector, expression cassettes were transferred to
pMV60, a shuttle vector for the generation of human type 5 recombinant ade-
noviruses (HuAd5 or A). These viruses were generated using a second plasmid,
pJM17, which contains the sequences of an E1, E3-deleted non-replicative
virus (kindly donated by Dr. F. Graham, McMaster University, Ontario,
Canada). The techniques used to generate these vectors and to produce vaccinia
(V) WR strain recombinants have been published elsewhere [9,22]. 
Cells. HEK-293 cells (CRL-1573; American Type Culture Collection,
ATCC, Manassas, VA) were used for the generation and propagation of
recombinant adenoviruses as well as for the generation of cell extracts for
Western-blot analyses. NIH/3T3 fibroblasts (CRL-1658; ATCC) were used
as antigen-presenting cells (APCs) in ELISPOT assays and for the in vitro
propagation of MCMV. L/Ld cells [8] (kindly donated by Dr. U.
Koszinowsky) were used as target cells in chromium-release assays.
Western-blot transfers. Proteins contained in extracts of HEK-293
cells infected with the different adenovirus constructs were separated by
SDS-PAGE and electrotransferred onto nitrocellulose membranes. The reac-
tivities of the proteins were tested using conventional techniques, chemilu-
miniscent reagents (ECL, GE-Amersham, USA), and an anti-HBe polyclon-
al serum raised in rabbits. 
Cell phenotype analyses by flow cytometry. Cells were stained
with anti-CD8 FITC-antibodies or MCMV-specific (YPHFMPTNL) MHC-I
H-2d phycoerythrin (PE)-tetramers as previously described [3]. Tetramers
were synthesized by ProImmune Limited (Oxford, UK). 
Real-time PCR. CMV and β-actin DNA were detected according to the
instructions contained in the Applied Biosystems SYBR Green PCR core kit
and using a 7700 Applied Biosystems real-time apparatus. The primer pairs
used were CMV (sense) 5′ TCAGCCATCAACTCTGCTACCAAC 3′ and
CMV (antisense) 5′ ATCTGAAACAGCCGTATATCATCTTG 3′ and β-actin
(sense) 5′ GGATGCAGAAGGAGATTACTG 3′ and β-actin (antisense)     5′
CGATCCAC ACAGAGTACTTG 3′.
Enzyme-linked ImmunoSPOT. ELISPOT assays were carried out
according to the protocol published by Carvalho et al. [6].
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Chromium-release assays. L/Ld cells compatible with a BALB/c
mouse genetic background were used as assay targets. To express foreign
protein antigens in recombinant vaccinia viruses, L/Ld cells were infected
with 5–20 PFU per cell for 16 h. Target cells were trypsinized and labeled
for 90 min with Na251CrO4, and a standard 3-h cytolytic assay was carried out
with 5000 target cells and graded numbers of cytolytic effector cells in
twofold dilution steps. Data represent the mean percentage of specific lysis
from three replicate cultures. 
Results
Analysis of antigen expression from virus-
infected cells. Recombinant proteins were produced by
four previously constructed [7–9] recombinant vaccinia
viruses expressing the protective CD8-T cell Ld epitope
YPHFMPTNL of MCMV flanked by five alanines, either at
the N or C-terminal regions of HBc or HBe proteins, and by
four newly constructed adenoviruses containing the same
recombinant sequences in their genomes.
The recombinant proteins expressed by these vectors
were named after their antigenic/secretory characteristics as
follows (Fig. 1A): HBe is the e antigen of HBV, a viral pro-
tein with intrinsic secretory properties due to the presence of
a pre-core sequence that serves as signal peptide; eN/A9A is
a secreted HBe chimera (e), in which the alanine-flanked
nonapeptide (A9A) of MCMV/pp89 was cloned in the N-ter-
minal portion of the protein (N/A9A). cC/A9A is a HBc
chimera that lacks a signal peptide—thus remaining as a cyto-
plasmic (c) form—but contains the MCMV motif included in
the C-terminal region (C/A9A) of the protein. A fourth
recombinant product, sC/A9A, is a HBc chimera based on
the C/A9A construction but engineered to express the
influenza virus hemagglutinin secretion signal (HASS),
which confers secretory (s) properties to this polypeptide. 
Sequencing of all viral genomes confirmed nucleic-acid
identities (data not shown), and Western-blot analyses of the
protein products separated by SDS-PAGE confirmed genera-
tion of the desired HBV recombinant products. The capacity
of the vaccinia viruses to express the recombinant products
was exhaustively tested in previous studies [8,9,11]. Thus,
Fig. 1B shows only the results of a representative Western-
blot analysis of cell extracts infected with the new aden-
oviruses. As seen in the figure, a polyclonal anti-HBe serum
that reacts both with HBe and HBc species yielded specific
bands in all cell extracts. The sizes of the different protein
products detected and their proportional intensities were
equivalent to those detected in recombinant vaccinia-infected
cells [11].
IMMUNIZATION AGAINST MCMV
Fig. 1. Chimeric MCMV/HBV antigens expressed by the recombinant adenoviruses and vaccinia viruses used
in the study. (A) Schematic representation of the components of the chimeric antigens, including the position
of the pp89 T cell epitope with respect to the C or N-terminal end, the alanine flanking sequences, and the
influenza virus hemagglutinin secretory signal (HASS). Numbers represent the relative position of the HBc
and HBe antigen sequences within the HBV genome. (B) Western-blot assay of extracts of HEK-293 cells
infected with the four recombinant adenoviruses. 
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Influence of antigen design on antigenicity. To
determine which form of the antigen was more efficient at
presenting the pp89 protective CD8 epitope to the immune
system, in vitro cytolysis assays were performed with the dif-
ferent vaccinia viruses. Figure 2A shows the results of an in
vitro chromium-release assay in which target cells were incu-
bated with each of the four recombinant vaccinia viruses
before being mixed with MCMV-specific in vitro
YPHFMPTNL-restimulated CTL clones. Cells infected with
each of the three viruses (HBc-cC/A9A, HBc-sC/A9A, and
HBe-N/A9A) were recognized and efficiently lysed by
YPHFMPTNL-specific lymphocytes, while no significant
specific lysis was detected when target cells were infected
with the recombinant virus expressing HBe. According to
this in vitro assay, there were no significant differences in the
presentation capacity of the CD8 epitope to the CTLs, prob-
ably because the numbers of MHC-I molecules loaded with
the CD8 peptide on the surface of target cells surpassed in all
cases the minimum amount required by the highly specific
lymphocytes to trigger a lysis reaction. 
In an attempt to better differentiate among presentation
capacities, the four recombinant adenoviruses were used to
immunize BALB/c mice and the in-vivo-induced cellular
immune response was then tested. Figure 2B shows that,
based on an ex vivo interferon IFNγ ELISPOT assay carried
out with splenocytes of mice immunized with these viruses,
the HBV chimera which best-presented the MCMV relevant
epitope was sC/A9A. 
Influence of the vector used on antigenicity.
Having established that the secreted form of the HBc/MCMV
chimera, i.e., the one containing influenza virus hemagglu-
tinin signal peptide, was the most immunogenic, we next
sought to determine the optimal vector for administering this
antigen in vivo. We therefore used not only the recombinant
adenovirus and vaccinia virus, but also a recombinant DNA
vaccine encoding the same antigen, since other researchers
reported significant induction of specific immunity with this
type of vector [12,25].
Figure 3 shows a representative result of ELISPOT assays
carried out using splenocytes of BALB/c mice immunized
with the optimal dose(s) and by the optimal route for each of
the vectors under study. There were significant differences
(up to five-fold) in the levels of antigen-specific CD8+ T cells
induced by the different vectors. The adenoviral vector was
the most immunogenic, as determined by the magnitude of
the cellular response, followed by the vaccinia virus and
finally the plasmid DNA vaccine.
Adenoviruses and vaccinia viruses used in
prime-boost protocols. We then examined whether
not only a switch between vectors, but also the use of a het-
erologous prime-boost protocol that had previously resulted
in excellent immunogenic capabilities in a murine malaria
model [3] could further increase the observed levels of
immunogenicity. For this, two types of viral vectors available
to vaccinate mice were used. Vaccination followed a precise
order; with the adenovirus administered first followed by the
vaccinia virus. Mice were immunized with an 8-week inter-
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Fig. 2. Immunogenicity of the MCMV/HBV chimeric antigens. (A) Chro-
mium-release assay carried out using labeled target cells infected with one
of the four vaccinia viruses and mixed with defined amounts of effector
pp89-specific CTLs. The assay was done twice and the value plotted is the
mean value of triplicate determinations for a given effector to target-cell
ratio (E:T). (B) ELISPOT assay to identify IFNγ-producing cells. Peptide-
incubated target cells were mixed with splenocytes of BALB/c-immunized
mice for 20 h before the second anti-IFNγ antibody was added to the wells
and the reaction was developed. Values represent the mean ± SD of triplicate
determinations. The experiment was done twice and nine animals were ana-
lyzed for each immunogen.
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val between the two vector administrations. We previously
found this interval to be a key factor in the optimal restimu-
lation of the primary immune response by booster adminis-
tration [3]. 
Figure 4 displays the results of the two assays in which
splenocytes of immunized mice were used to test our hypoth-
esis. In the first, an IFNγ ELISPOT was carried out using the
synthetic peptide YPHFMPTNL (Fig. 4A); the second con-
sisted of a flow cytometric approach using peptide-loaded
fluorescent tetrameric Ld MHC-I complexes (Fig. 4B). As
shown in Fig. 4A, significant numbers of antigen-specific
IFNγ-producing CD8+ T cells were induced in mice immu-
nized with vaccinia virus expressing sC/A9A. However, as
previously shown, the numbers of T cells induced by this
vector were appreciably lower than those induced by the ade-
noviral recombinant. In support of our hypothesis, sequential
administration of the two vectors in a prime-boost approach
induced much higher levels of antigen-specific IFNγ-produc-
ing CD8+ T cells than either of these vectors administered
individually. The boosted levels of CD8+ T cells were at least
four times higher than the number of these cells induced by
the adenoviral vector alone and six to ten (data not shown)
times higher than obtained with the vaccinia vector. Flow
cytometric analyses corroborated these findings. Figure 4B
consists of four representative panels listing the percentages
of antigen-specific CD8+ T cells elicited by vaccination of
BALB/c animals, either mock-immunized or immunized
with the adenoviral vector, the vaccinia vector, or according
to the heterologous protocol described above. While viral
vectors administered as a single dose already induced signif-
icant levels of double-labeled fluorescent cells, sequential
IMMUNIZATION AGAINST MCMV
Fig. 3. Direct comparison of the immunogenicity of different recombinant
vectors expressing sC/A9A, as measured by an ELISPOT assay carried out
with splenocytes of BALB/c mice immunized with the recombinant plasmid
DNA (three doses of 100 μg per mouse), vaccinia (V, i.p. 5 × 107 PFU/mouse),
or adenoviral vector (A, i.d. 5 × 108 PFU/mouse). Results are the mean ± SD
and are representative of two experiments with three animals per group in each
experiment.
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Fig. 4. Immunogenicity of the heterologous prime-boost protocol consisting
of adenovirus and vaccinia virus expressing sC/A9A. Adenovirus (A) and
vaccinia (V) vectors were inoculated in BALB/c mice individually or
sequentially (A-V) at an 8-week interval and their splenocytes were tested in
(A) IFNγ ELISPOT assays in which target cells were incubated with peptide
YPHFMPTNL; values represent mean ± SD of six determinations and are
representative of three experiments with a total of ten animals. (B) Flow-
cytometry analyses of splenocytes incubated with FITC-labeled anti-CD8
antibodies and phycoerythrin-labeled, YPHFMPTNL-loaded MHC-I Ld
tetramers. Numbers represent the mean values of four animals and triplicate
determinations.
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administration of the vectors in the order A-V and within an
8-week interval rendered CD8+ T cells of which over 30%
were specific for the desired antigen in the spleen. 
Protection of immunized animals against
challenge with infectious MCMV. As with any
other vaccine, more important than the immune results is the
ability of the inoculation to confer protection against the cor-
responding pathogenic infection. To test whether immuniza-
tion with our vectors, separately or following our highly
immunogenic prime-boost protocol, was protective against
infection, immunized BALB/c mice were inoculated with
infectious MCMV.
To mimic a realistic setting, and since cytomegalovirus
infection is never acquired as a lethal dose, the animals were
challenged with sublethal doses (2 × 104 PFU/mouse). Thus,
to determine the efficiency of the vaccinations, a sensitive
technique able to detect small loads of virus in animal organs
was needed. Liver, lungs, salivary glands, and spleens were
tested in a real-time PCR assay to determine the adequacy of
this technique. All organs were positive in animals that had
been challenged with the sublethal dose of virus (data not
shown). Spleen was chosen as the target organ because it can
be readily isolated and processed. 
A real-time PCR assay was carried out in which
sequences of the MCMV genome and of the reporter gene
β-actin were amplified simultaneously, so that the latter
could be used to normalize the levels of the former. In addi-
tion, the target fragment of MCMV was cloned in a plasmid
vector, yielding a molecule of defined molecular weight and
in accurately measurable concentrations such that a standard
curve allowing precise quantification of the samples could be
constructed. 
The two panels in Fig. 5A show the dissociation curves
obtained after real-time PCR amplification using SYBR
Green I as fluorophore to detect MCMV and β-actin PCR-
amplified products. Single peaks of fluorescence were
observed for each sample tested according to the PCR prod-
Fig. 5. Protection against MCMV infection elicited by a prime-boost protocol consisting of a recombinant adenovirus and a vaccinia virus, both encoding
sC/A9A. (A) Dissociation curves of the MCMV-amplified (left) and β-actin-amplified (right) products labeled with SYBR Green I. The characteristic dis-
sociation temperatures of the double-stranded DNA molecules as defined by the specific peaks are indicated. (B) Left panel: standard curve constructed with
serial dilutions of a plasmid in which the product of a MCMV PCR amplification was cloned. The number of plasmid molecules added to the reaction ver-
sus the threshold cycle value (CT) obtained for each amount of molecules is plotted. Right panel: viral loads detected in the spleens of BALB/c mice immu-
nized according to the most immunogenic protocols and then challenged with 2 ×104 PFU of MCMV/mouse. Numbers represent mean ± SD of triplicate
determinations. The percent reductions in the viral loads due to the efficiency of the different immunization regimes are shown in the lower right side of the
figure. Doses and abbreviations are as explained in Fig. 3.
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uct that had been amplified. Each PCR product displayed a
single characteristic melting temperature, indicating that the
amplification reactions were highly specific.
Figure 5B (left panel) shows the results of the analysis of
different numbers of plasmid copies by real-time PCR assay.
The dynamic range (tested from 100 to 108, displayed from
104 to 108) and the correlation factor (r2 = 0.995) obtained
with the technique were high enough to assure accurate quan-
tification of the samples. Using this standard curve, we quan-
tified the levels of MCMV in spleens of BALB/c mice immu-
nized according to the different protocols (Fig. 5B, right
panel). High viral loads were detected in the spleens of con-
trol animals 6 days after challenge with MCMV. Much lower
levels of virus were detected in spleens of vaccinia virus
sC/A9A-immunized (V) animals, representing a reduction of
73% of the viral load found in littermate control mice.
Adenovirus sC/A9A-immunized mice displayed a significant
81% reduction in viral load. As expected, the highest reduc-
tion of viral load (96%) was detected in the spleens of ani-
mals immunized according to the adenovirus/vaccinia prime-
boost protocol. 
Discussion
In this study, four recombinant adenoviruses containing
chimeric HBV/MCMV constructions equivalent to those pre-
viously included in vaccinia viruses were designed and then
tested for their capacity to express the transgenes and to pres-
ent a protective CD8+ T-cell epitope of MCMV. The recom-
binant proteins were readily expressed and did not differ
from those previously obtained with recombinant vaccinia
viruses. The capacity of the different constructs to present the
relevant MCMV CD8 epitope was investigated using cytoly-
sis and ELISPOT assays. In vitro cytolysis assays did not
discriminate processing/presentation abilities, in contrast to
the ELISPOT assays of the in vivo induction of immune
responses.
Cytolysis assays are based on the recognition of antigen-
presenting target cells by MCMV-specific T-cell clones
induced after several in vitro restimulation steps. In this set-
ting, highly avid lymphocytes react with target cells, and it
has been demonstrated that under these conditions less than
one hundred MHC/peptide complexes on the target-cell sur-
face are able to trigger a cytolytic reaction [24]. Since all the
vaccinia viruses used in the assays described here are very
efficient at processing the relevant peptide [11], the fact that
no differences among vectors were detected could have been
due to the high number of complexes that any of the vaccinia
viruses might have generated.
In contrast, the ELISPOT assays were capable of discrim-
inating different processing and presentation activities of the
chimeric proteins because these assays determine the number
of lymphocytes induced in vivo by the vaccines; this process
includes several bottlenecks that separate efficient from inef-
ficient combinations of vectors/antigens. An example of one
of these in-vivo optimal vaccine-filtering processes is cross-
presentation of secreted antigens such as sC/A9A by dendritic
cells. 
The ELISPOT assays therefore allowed us to confirm
previous observations [8,11], that the secreted form of HBc
encompassing the relevant T-cell epitope in the C-terminal
end of the protein and flanked by five alanine residues was
the most efficiently presented. The efficiency of this con-
struct may have something to do with either or all of the fol-
lowing processing/presentation events: (i) processing and
presentation of the antigen by TAP-dependent and independ-
ent mechanisms [11], since sC/A9A is a substrate for all
immune-relevant proteases and thus the chances are high that
it will correctly load MHC-I molecules; (ii) secretion increases
the opportunities for cross-presentation as well as the support
of CD4+ T cells in the generation of CD8+ T cells; or (iii)
sC/A9A represents a secreted HBc chimera that forms parti-
cles engulfed by the appropriate CD8-related APCs.
Vaccinia viruses and DNA vaccines have been used to
immunize against MCMV and induce significant levels of
cellular immunity. Since in our experiments adenoviruses
served as excellent immunogens [2–5,19], an additional goal
of this study was to directly compare the immunogenicity of
the three vectors. Indeed, adenoviruses were more immuno-
genic than the two other types of vectors tested. This may
have been due to: (i) the presence of proteins with adjuvant
activity in the virion itself [14,23], (ii) the ability of this non-
replicative virus to infect APCs [1] without inducing extreme
pathologic alterations or the blockade of cell functionality,
and (iii) the promiscuity of infection and the high levels of
transgene expression that flood the host with antigen for a
short period of time, thereby inducing strong immune
responses but avoiding the development of tolerance or
exhaustion events because of excessive induction of the
immune system.
Despite the potent immune response induced by
poxviruses alone in vaccination protocols, previous studies in
a malaria model showed that, when these viruses are included
as boosters in prime-boost protocols that include recombi-
nant adenoviruses, immune levels are increased even further.
Moreover, when poxviruses are included in the vaccination
protocols, they tend to generate more homogeneous results.
The lack of homogeneous results is a frequent occurrence
and represents an intrinsic problem for immunization vectors
IMMUNIZATION AGAINST MCMV
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such as DNA vaccines [12]. This was also the case in our
experiments, as evidenced by the large standard deviation of
the corresponding results shown in Fig. 3. ELISPOT assays
confirmed that a single dose of either of the two viruses that
expressed the optimized sC/A9A antigen was more immuno-
genic and produced a more homogeneous response than three
doses of the equivalent DNA vaccine. 
Prime-boost protocols consisting of adenovirus and vac-
cinia virus induced high levels of cellular immune responses
against the relevant CD8 epitope of the MCMV pp89 protein.
These responses had a Th1 profile and were characterized by
the production of large quantities of IFNγ and tumor necrosis
factor TNF-α (data not shown), both of which are significant
for the host’s ability to fight off a viral infection. Although
not directly relevant for the present study, which focused on
the induction of cellular immunity, it should be noted that
immunizations with the recombinant viruses also induced
high titers of antibodies against the HBV carrier proteins
(data not shown). Therefore, prime-boost protocols that use
these vectors are also very efficient at inducing humoral
immune responses. 
Finally, protection against MCMV infection was tested in
this study by inoculating vaccinated animals with infectious
viruses, albeit in a manner different from the traditional use
of two to four lethal doses (LD50) in a life/death challenge.
Instead, our goal was to test the efficacy of the vaccination
protocols in a realistic setting. Furthermore, the administra-
tion of a lethal challenge is not very sensitive at differentiat-
ing immunogens that induce high levels of immunity, as was
confirmed here. Thus, alternatively, a real-time quantitative
PCR approach was used to determine viral loads in immu-
nized mice that had been challenged with a sublethal MCMV
dose. This technique proved to be very specific, sensitive,
and accurate, differentiating a broad range of viral loads in
challenged animals. The assays used spleen extracts because
the spleen can be easily manipulated. Furthermore, it was
previously shown that the capacity to control MCMV repli-
cation in the spleen during the first days after infection is a
surrogate response that correlates extremely well with further
control of viral infection [18]. Titration of the virus was not
used to determine viral load since it tends to underestimate
viral number in the challenged animal, due to inactivation of
viral particles during the homogenization and culture-infec-
tion processes. By contrast, the real-time technique allowed
us to demonstrate that a prime-boost protocol based on
recombinant adenovirus and vaccinia virus is a highly effi-
cient immunizing tool and has a strong capacity to reduce the
viral load in infected animals.
Taken together, our results confirm previous observations
on the efficacy of combining adenoviruses and poxviruses in
prime-boost protocols and suggest the use of these protocols as
one of the best approaches to induce T-cell responses against dis-
eases caused by intracellular pathogens. 
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